Clinical Trials
Closed Recruiting
-
Sitravatinib (MGCD516) and Nivolumab in Oral cavity cancer Window opportunity study (SNOW)Eligible Tumour Type(s): Squamous Cell Carcinoma of the Oral Cavity
Sponsor: In-house
Principal Investigator: Lillian Siu
NCT#: NCT03575598 -
TILs-001-DC
A Phase I Study evaluating the feasibility and safety of infusion of Re-StimulatedAutologous tumor-infiltrating lymphocytes (TILs) followed by low-dose interleukin-2 therapy in patients with platinum resistant high grade serous ovarian, fallopian tube, or primary peritoneal cancer
Sponsor: In-House
Principal Investigator: Marcus Butler
NCT#: NCT01883297
-
TILs-002-MEL
Phase II Study evaluating the infusion of autologous tumor-infiltrating lymphocytes (TILs) and low-dose interleukin-2 (IL-2) therapy following a preparative regimen of non-myeloablative lymphodepletion using cyclophosphamide and fludarabine in patients with metastatic melanoma.
Sponsor: In-House
Principal Investigator: Marcus Butler
NCT#: NCT01883323
https://clinicaltrials.gov/ct2/show/NCT01883323?term=TILs-002-MEL&rank=1
-
TILs-003-Meso
Phase I/II study evaluating the infusion of tumor-infiltrating lymphocytes (TILs) and low-dose interleukin-2 (IL-2) therapy following a preparative regimen of non-myeloablative lymphodepletion using cyclophosphamide and fludarabine in patients with malignant pleural mesothelioma)
Sponsor: In-House
Principal Investigator: Marcus Butler
NCT#: NCT02414945
https://clinicaltrials.gov/ct2/show/NCT02414945?term=TILs-003-Meso&rank=1
-
INSPIRE
INvestigator-initiated Phase II Study of pembrolizumab immunological response evaluation
Sponsor: In-House
Principal Investigator: Lillian Siu
NCT#: NCT02644369
-
ACTIVATE
Phase Ib trial of pembrolizumab administered in combination or following adoptive cell therapy: A multiple cohort study
Sponsor: In-House
Principal Investigator: Marcus Butler
NCT#: NCT02811497
-
METADUR
An open-label, phase II basket study of a hypomethylating agent azacitidine and durvalumab (anti-PDL1) in advanced solid tumors.
Sponsor: In-House
Principal Investigator: Lillian Siu
NCT#: NCT02811497